The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TMCI | +33.66% | N/A | N/A | -73% |
| S&P | +16.23% | +94.45% | +14.22% | +61% |
Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. It offers Lapiplasty, a bunion surgery for three-dimensional bunion correction. It operates and distributes its products and services under the following trademarks: Treace Medical Concepts, Lapiplasty, Fast Grafter, Align My Toe, The Future of Hallux Valgus, Fix It Right The First Time, and Plantar Python. The company was founded by John T. Treace in July 2013 and is headquartered in Ponte Vedra Beach, FL.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $47.39M | 6.6% |
| Gross Profit | $37.75M | 5.8% |
| Gross Margin | 79.67% | -0.6% |
| Market Cap | $369.88M | -10.3% |
| Market Cap / Employee | $0.78M | 0.0% |
| Employees | 477 | -7.6% |
| Net Income | -$17.40M | 18.0% |
| EBITDA | -$14.40M | 25.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $8.05M | -55.7% |
| Accounts Receivable | $30.33M | 18.7% |
| Inventory | 42.4 | 2.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $66.89M | -3.7% |
| Short Term Debt | $3.20M | 715.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -22.74% | 4.0% |
| Return On Invested Capital | -23.36% | -2.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$7.82M | 50.0% |
| Operating Free Cash Flow | -$3.05M | 78.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.44 | 4.42 | 4.63 | 3.51 | 7.74% |
| Price to Sales | 1.78 | 2.22 | 2.49 | 1.73 | -16.65% |
| Price to Tangible Book Value | 4.31 | 5.53 | 5.69 | 4.37 | 11.11% |
| Enterprise Value to EBITDA | -26.84 | 225.18 | -39.56 | -25.79 | 28.16% |
| Return on Equity | -50.7% | -44.4% | -45.7% | -46.9% | -3.50% |
| Total Debt | $70.12M | $69.65M | $69.36M | $70.09M | 0.35% |
TMCI earnings call for the period ending June 30, 2022.
TMCI earnings call for the period ending March 31, 2022.
TMCI earnings call for the period ending December 31, 2021.
TMCI earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
